Featured Research

from universities, journals, and other organizations

New Radioimmunotherapy Drug Proves Highly Effective For Killing Off B Cell Non-Hodgkin's Lymphoma

Date:
May 14, 2002
Source:
Mayo Clinic
Summary:
A Mayo Clinic study indicates the first of a new class of drugs involving radioimmunotherapy benefited a significant number of patients with low-grade B cell non-Hodgkin’s lymphoma who have exhausted treatment options.

ROCHESTER, MINN. -- A Mayo Clinic study indicates the first of a new class of drugs involving radioimmunotherapy benefited a significant number of patients with low-grade B cell non-Hodgkin’s lymphoma who have exhausted treatment options.

The study, published in the May 15, 2002, issue of Journal of Clinical Oncology, investigated the ability of the drug Zevalin to hone in on and kill off the non-Hodgkin’s lymphoma B cells. Zevalin is the first radioimmunotherapy drug developed specifically to fight this common but usually fatal cancer of the lymph glands that, for unknown reasons, is on the increase in the United States. About 56,000 people are diagnosed with this cancer annually.

The randomized study involved 143 patients with B cell non-Hodgkin’s lymphoma who had previously failed the standard chemotherapy treatments. The study found that 80 percent of patients who received Zevalin experienced a positive response in that their tumor shrunk. That compared to a 56 percent response rate in patients receiving only Rituxan, another drug used to treat the cancer.

Most noteworthy, 30 percent of the patients receiving Zevalin achieved complete remission with no evidence of the cancer present, compared to only 16 percent of patients taking Rituxan.

Radioimmunotherapy combines monoclonal antibodies, which are antibodies produced in a laboratory to react against a cancer cell, with the ability of radiation to kill off cancer cells. The mixture of radiation and antibodies is given intravenously and travels through the bloodstream to the cancer cells.

“Unlike chemotherapy which goes through the whole body, Zevalin carries the radiation payload directly to the tumor,” says Thomas Witzig, M.D., a Mayo Clinic hematologist. “The drug radiates only about a five millimeter area around the tumor.”

Along with its ability to hone in on cancer cells, the drug is easier on patients physically.

“One treatment is required on an outpatient basis, compared to a series of treatments with chemotherapy that can last four to six months and sometimes include hospitalization because of serious side effects,” says Dr. Witzig. “There’s no hair loss or prolonged fatigue, nausea or vomiting. The most significant side effect is a temporary decrease in the blood count.”

Dr. Witzig and Gregory Wiseman, M.D., a Mayo Clinic nuclear medicine specialist, led the phase III research study. This study was one of several clinical trials on the drug conducted by Mayo Clinic and nine other cancer centers in the United States. The cumulative results led to the recent approval of Zevalin by the Food and Drug Administration for treatment of patients with relapsed B cell non-Hodgkin’s lymphoma.

Non-Hodgkin’s lymphoma ranks as the fifth most common type of cancer diagnosed in the United States. However, while incidences of most cancers have been decreasing in the past couple of decades, the number of patients diagnosed with non-Hodgkin’s lymphoma has been steadily increasing.

An estimated 300,000 Americans are currently living with the disease. Most of the patients are age 40 and older. In patients aged 60 years and older, the incidence of non-Hodgkin’s lymphoma is about 100 patients per 100,000 people. Zevalin is manufactured by IDEC Pharmaceuticals Corporation.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "New Radioimmunotherapy Drug Proves Highly Effective For Killing Off B Cell Non-Hodgkin's Lymphoma." ScienceDaily. ScienceDaily, 14 May 2002. <www.sciencedaily.com/releases/2002/05/020514074113.htm>.
Mayo Clinic. (2002, May 14). New Radioimmunotherapy Drug Proves Highly Effective For Killing Off B Cell Non-Hodgkin's Lymphoma. ScienceDaily. Retrieved September 20, 2014 from www.sciencedaily.com/releases/2002/05/020514074113.htm
Mayo Clinic. "New Radioimmunotherapy Drug Proves Highly Effective For Killing Off B Cell Non-Hodgkin's Lymphoma." ScienceDaily. www.sciencedaily.com/releases/2002/05/020514074113.htm (accessed September 20, 2014).

Share This



More Health & Medicine News

Saturday, September 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com
How The 'Angelina Jolie Effect' Increased Cancer Screenings

How The 'Angelina Jolie Effect' Increased Cancer Screenings

Newsy (Sep. 19, 2014) Angelina's Jolie's decision to undergo a preventative mastectomy in 2013 inspired many women to seek early screenings for the disease. Video provided by Newsy
Powered by NewsLook.com
The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins